Literature DB >> 23731881

Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae.

Thomas Karlas1, Johannes Wiegand, Thomas Berg.   

Abstract

Obesity is a major risk factor for malign and non-malign diseases of the gastrointestinal tract. Non-alcoholic fatty liver disease (NAFLD) is an outstanding example for the complex pathophysiology of the metabolic system and represents both source and consequence of the metabolic syndrome. NAFLD has a growing prevalence and will become the leading cause of advanced liver disease and cirrhosis. Obesity has a negative impact on NAFLD at all aspects and stages of the disease. The growing epidemic will strain health care resources and demands new concepts for prevention, screening and therapeutic approaches. A better understanding of the interplay of liver, gut and hormonal system is necessary for new insights in the underlying mechanisms of NAFLD and the metabolic syndrome including obesity. Identification of patients at risk for progressive liver disease will allow a better adaption of treatment strategies.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23731881     DOI: 10.1016/j.beem.2013.02.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  19 in total

1.  Candy consumption in childhood is not predictive of weight, adiposity measures or cardiovascular risk factors in young adults: the Bogalusa Heart Study.

Authors:  C E O'Neil; T A Nicklas; Y Liu; G S Berenson
Journal:  J Hum Nutr Diet       Date:  2013-12-30       Impact factor: 3.089

2.  USF-1 genetic polymorphisms confer a high risk of nonalcoholic fatty liver disease in Chinese population.

Authors:  Ying Wang; Bai-Fang Wang; Jing Tong; Bing Chang; Bing-Yuan Wang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 3.  Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver.

Authors:  Philipp Lutz; Hans Dieter Nischalke; Christian P Strassburg; Ulrich Spengler
Journal:  World J Hepatol       Date:  2015-03-27

4.  Visceral abdominal obesity is associated with an increased risk of irritable bowel syndrome.

Authors:  Chang Geun Lee; Jun Kyu Lee; Yun-Seong Kang; Seungmin Shin; Jae Hak Kim; Yun Jeong Lim; Moon-Soo Koh; Jin Ho Lee; Hyoun Woo Kang
Journal:  Am J Gastroenterol       Date:  2015-01-13       Impact factor: 10.864

Review 5.  Herbal medicines and nonalcoholic fatty liver disease.

Authors:  Hong Yao; Yu-Jie Qiao; Ya-Li Zhao; Xu-Feng Tao; Li-Na Xu; Lian-Hong Yin; Yan Qi; Jin-Yong Peng
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 6.  Therapies in non-alcoholic steatohepatitis (NASH).

Authors:  Abdul M Oseini; Arun J Sanyal
Journal:  Liver Int       Date:  2017-01       Impact factor: 5.828

Review 7.  Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.

Authors:  Judith Aron-Wisnewsky; Chloé Vigliotti; Julia Witjes; Phuong Le; Adriaan G Holleboom; Joanne Verheij; Max Nieuwdorp; Karine Clément
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-09       Impact factor: 46.802

Review 8.  Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease.

Authors:  Zobair M Younossi; Linda Henry
Journal:  Pharmacoeconomics       Date:  2015-12       Impact factor: 4.981

Review 9.  Mechanisms Linking Inflammation to Insulin Resistance.

Authors:  Li Chen; Rui Chen; Hua Wang; Fengxia Liang
Journal:  Int J Endocrinol       Date:  2015-06-02       Impact factor: 3.257

10.  Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy.

Authors:  Thomas Karlas; David Petroff; Nikita Garnov; Stephan Böhm; Hannelore Tenckhoff; Christian Wittekind; Manfred Wiese; Ingolf Schiefke; Nicolas Linder; Alexander Schaudinn; Harald Busse; Thomas Kahn; Joachim Mössner; Thomas Berg; Michael Tröltzsch; Volker Keim; Johannes Wiegand
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.